Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting the hepatitis delta viral (HDV) genome developed using Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHepatitis D virus (HDV)
Indication DetailsTreat hepatitis delta virus (HDV) infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today